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ABSTRACT
Wilson, Caitlin. M.S. Microbiology and Immunology, , Wright State University, 2016. The Expres-
sion of Major Histocompatibility Class I and Major Histocompatibility Class II on Macrophages in
the Presence of Aryl Hydrocarbon Antagonist (CH-223191).
Macrophages are crucial for ridding the body of debris and foreign cells. The aryl
hydrocarbon receptor (AhR) also plays a critical role in immunity. This study exam-
ined the effect of the AhR on the expression of major histocompatiability complex class
I (MHCI) and MHC class II (MHCII) in two murine macrophage cell lines. This study
used Raw264.7 and J774A.1 murine macrophage cell lines. The Raw264.7 cells are from
male BALB/c mice while the J774A.1 cells are from female BALB/cN mice. The addition
of the AhR anatagonist CH-223191 (AhRa) showed that the AhR does not significantly
impact MHCI expression. However, MHCII expression was decreased by the addition of
AhRa in Raw264.7 cells, while MHCII expression was significantly increased in J774A.1
cells after AhRa addition. During the course of the study, trypan blue results showed in-
creased cell survival in classically activated macrophages. Therefore, early apopotosis, late
apoptosis, and necrosis were examined by annexin V and propidium iodide analysis. Cell
death analysis showed increases in late apoptosis for both cell lines after the addition of
AhRa, suggesting the AhR plays a role in cell survival during macrophage activation. This
study shows that even basal levels of AhR expression can impact MHCII expression and
apoptosis of murine macrophages.
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Macrophages are some of the first immune cells to respond to infection and are impor-
tant for the phagocytosis of cellular debris as well as antigen presentation to T and B
cells [19]. When macrophages are stimulated by other leukocytes, they communicate by
releasing anti-inflammatory cytokines such as interleukin (IL)-4, IL-10, and IL-13 or in-
flammatory cytokines such as TNFα, IL-12, or IL-18 [76]. IFNγ is typically secreted
by natural killer (NK) cells, activated CD8+ cytotoxic T cells, or CD4+ T helper cells
and is used to communicate with macrophages. Then the macrophages release IL-12 and
IL-18 to simulate the NK cells to produce more IFNγ [42, 76]. Macrophages can then
be stimulated with anti-inflammatory cytokines such as IL-4, IL-10, or IL-13 by either
other nearby macrophages, T cells, or B cells in order to control the immune response
[18]. Macrophages that are stimulated with LPS and IFNγ are considered to be classi-
cally activated (M1), while macrophages activated by IL-4, IL-10, or IL-13 are considered
alternatively activated (M2) [76].
Classically activated macrophages are stimulated by binding LPS, which triggers the
toll like receptor 4 (TLR4) pathway [50]. The TLR4 pathway results in the up-regulation
of genes for MHCII expression and IFNγ expression [6]. If IFNγ is released by other
immune cells, it triggers the JAK/STAT pathway and upregulates both MHCI and MHCII
on macrophages and other antigen presenting cells (APCs) [61]. In order for macrophages
to perform antigen presentation, they need to express MHCI and MHCII [25]. MHCI is
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expressed on all cells and is used by natural killer cells to differentiate between cells that
are considered self (normal cells) and non-self (cancer cells or foreign cells) [23]. MHCII
is expressed on APCs and is used in antigen presentation to CD4+ T cells [24, 54]. MHCI
and MHCII expression has to be tightly controlled in order to ensure the immune system
does not ignore cancer cells or cause autoimmune diseases [47].
This study examined the relationship between the AhR and the expression of MHCI
and MHCII on two murine macrophage cell lines. Vorderstrasse et al. [74, 75] found that
MHCII expression on dendritic cells was increased when cells were treated with 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in the presence and absence of antigen. Since macrophages
are cousins to dendritic cells and share many common features, my objective was to explore
the effects of cytokines and AhR antagonist on macrophages. Because macrophages have
the ability to remain plastic throughout their life cycle, researchers can benefit from a better
understanding of the mechanisms that regulate this plasticity. In this study I aimed to better
define the relationship between the AhR and the process of macrophage activation. MHCI
and MHCII molecules were chosen for examination because they are a necessary part of
antigen presentation.
The aryl hydrocarbon receptor (AhR) has been studied in many capacities. The AhR
has been implicated in oxidative stress, cell cycle regulation, apoptosis, and several pro-
cesses of immune cell function [43, 45]. The primary models for studying the effects of
the AhR on the innate immune system have been dendritic cells and macrophages. Both
are phagocytic cells that are capable of producing cytokines for communication with other
leukocytes, and both can present antigen to lymphocytes [30]. The AhR crosstalks with
many pathways, including the TLR4 pathway and the NFκB pathway [33, 73]. Vogel et al.
[73] found that the AhR directly interacts with RelB (an NFκB subunit) and this interac-
tion is increased in cells treated with TCDD. Conversely, when AhR knock out cells were
tested this interaction was suppressed [73]. Suppression of this interaction impacted the
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development and maturation of the dentritic cells [73]. Kimura et al. [33] report that the
AhR interacts with NFκB and stat1 in the presence and absence of LPS (an endogenous
ligand). This interaction appears to control the inflammatory response of LPS and TLR4
signaling as the team found that a stat1 deficiency caused an increase in LPS-induced IL-6
production and a decrease in LPS-induced IL-10 production [33].
To test the impact of the AhR on MHCI and MHCII expression, I administered AhR
antagonist (AhRa) CH-223191 to macrophages in order to competitively inhibit the AhR.
CH-223191 was chosen over other AhR antagonists such as flavone, reservatrol, or α-
naphthoflavone because other antagonists can cause cytotoxicity at high concentrations,
but CH-223191 does not exhibit this property even at concentrations of 100µM [31]. CH-
223191 is thought to act by binding to the ligand binding pocket of the AhR in a location
similar to halogenated aromatic hydrocarbon (HAH) ligands [9]. This binding prevents the
AhR from making a confirmational change and binding DNA [9]. CH-223191 was cho-
sen for this study because it is less likely to induce cytotoxcicity against the macrophages
compared to other antagonists.
This study focused on the endogenous role of the AhR without ligand stimulation. I
postulated that treatment with AhR antagonist would lead to decreased MHCII expression
in macrophages because dendritic cells treated with TCDD showed an increase in MHCII
expression [75]. I found no evidence in scientific literature that showed an increase or
decrease of MHCI expression in cells treated with AhR antagonist or AhR ligands, thus I
postulated there would be minimal changes in MHCI expression. During the course of the
study I also explored the effects of the AhRa on cell viability after I noticed an increased
viability in cells treated with AhRa, LPS and IFNγ. I speculated that both M1 and M2 cells
would show an increase in cell viability after AhRa treatment.
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Hypothesis
I hypothesize that AhR antagonism will have no effect on the number of MHCI receptors,
but will decrease the number of MCHII receptors.
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Literature Review
3.0.1 The Function of Macrophages
Macrophages are phagocytic cells that evolved over 500 million years ago [19]. They are
an important part of the innate immune system. These cells are some of the first immune
cells to respond to infection and are critical for communication between the innate and
adaptive immune systems. Macrophages are able to respond quickly to infection because
monocytes migrate to tissues and take up residence when tissues are formed during embry-
onic development. These resident tissue macrophages are distinct from macrophages that
develop in the bone marrow and can be self renewing in specific organs, such as microglial
cells in the brain [19].
In general, macrophage development starts in the bone marrow. When the cells are de-
veloped enough to leave the bone marrow, the cells are called monocytes [21]. Monocytes
circulate in the blood stream until they are called into tissues via cytokines and chemokines
released into the bloodstream [21]. Once the monocytes migrate into tissues, they become
macrophages [21]. Macrophages can be found in every tissue of the body and some tissues
have multiple types of macrophages that work together [19]. For example, dust cells are
resident macrophages that reside in the lungs, while Kupffer cells are specific to the liver,
and microglial cells can be found in the brain. These resident macrophages are the first to
respond to an infection, and can release cytokines or chemokines to call in monocytes as
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well as other lymphocytes from the blood to help quell the infection.
A macrophage’s main function is phagocytosis of cellular debris and antigen presen-
tation to T cells and B cells [49]. Macrophages accomplish these tasks through cytokines
released by other immune cells and other nearby macrophages [49]. Cytokines can have a
wide variety of effects on differentiated macrophages. Anti-inflammatory cytokines such
as IL-4, IL-10, and IL-13 promote healing and tissue remodeling [76]. In contrast, inflam-
matory cytokines like IFNγ stimulate macrophages to phagocytose organisms or debris and
destroy them [36]. Macrophages require LPS and IFNγ to be fully activated, allowing the
macrophage to process and present antigenic peptides of the killed organism to T and B
cells [36]. This process is called antigen presentation.
The unique ability of macrophages to switch between wound healing and pathogen
destruction makes them critical for immune system regulation. Researchers classify
macrophages in the inflammatory state as M1 macrophages, while cells in the anti-
inflammatory state are called M2 macrophages [76]. The M2 state has three further sub-
divisions. Macrophages classified as M2a are activated by IL-4 and IL-13 [76]. M2a cells
are important in wound healing [76]. M2b cells are activated by IL1-R and Toll like recep-
tor (TLR) agonists and these cells regulate immune function [76]. Finally, IL-10 induces
M2c cells, which are important for tissue remodeling and response to parasitic infections
[45, 76].
3.0.2 Anti-inflammatory cytokines: IL-4, IL-10, and IL-13
Anti-inflammatory cytokines are produced by macrophages and other immune cells such as
basophils, eosinophils, T helper type (Th)2 CD4+ T cells, B lymphocytes and monocytes
[40, 76]. These cytokines are critical for tissue healing, controlling complement response,
and keeping M1 macrophages in check [76]. M2 polarized cells will also respond to inter-
nal parasites and kill actively dividing tumors [68].
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Macrophages activated by IL-4 and IL-13 are categorized as M2a macrophages. IL-4
and IL-13 have similar functions, possibly because they share the same receptor (IL-4Rα)
and they both activate the STAT6 pathway [66]. Both IL-4 and IL-13 are used to control in-
flammation and are commonly found when examining allergic reactions [66, 71]. Thivierge
et al.[66] found that both IL-13 and IL-4 can contribute to the activation of M2 macrophages
during allergic reactions and asthma, helping to maintain the anti-inflammatory state. Vere-
meyko et al. [71] also found that IL-4 is required for the maintenance of the M2 state. These
cells have also been found to protect against organ failure by down regulating inflammation
[68].
IL-4 and IL-13 are important for inducing and maintaining the anti-inflammatory state.
For example, IL-13 down-regulates the expression of CD14, which is involved in binding
LPS [14]. This down-regulation helps to suppress activation of the TLR4 signaling path-
way. IL-4 and IL-13 also act as mediators between the innate and adaptive immune system.
Both cytokines have the ability to up-regulate the expression of MHCII, and this expression
can be inhibited by the addition of IL-10 or IFNγ [14]. IL-4 and IL-13 can also induce B
cell class switching to IgE antibodies [14, 51]. Type I allergic reactions are mediated by
IgE antigen interactions with mast cells, T helper type I cells, and macrophages [4]. It
appears that IL-4 and IL-13 are important mediators for balancing the inflammatory and
anti-inflammatory states of macrophages.
Unlike IL-4 and IL-13, IL-10 strongly suppresses MHCII expression as well as CD80
and CD86 [40, 65]. CD80 and CD86 are involved in co-stimulation of T cells and both
are required for T cell survival and maintenance [65]. IL-10 also induces the expression
of Membrane-associated RING-CH (MARCH) proteins, which ubiquitinate the tails of
MHCI, MHCII, and CD86 [65]. This ubiquitination marks these receptors for destruction,
down-regulating the expression of these molecules on the cellular surface [65]. IL-10 can
also keep MHCII molecules from being up-regulated by preventing the mature MHCII
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molecules from reaching the outer surface on the plasma membrane of human monocytes
[35]. During pregnancy, IL-10 suppresses expression of classical MHCI and MHCII and
induces expression of HLA-G [40]. HLA-G receptors are expressed by the fetus during
pregnancy because classical MHCI receptors would lead to the mother’s immune system
rejecting the fetus [40]. Pregnancies with lower than average counts of IL-10 have higher
frequencies of termination [40].
IL-4, IL-10 and IL-13 have all been shown to inhibit the production of IL-l α, IL-lβ,
and TNF-α [14]. All of these cytokines promote inflammation and thus IL-4, IL-10, and
IL-13 exhibit anti-inflammatory properties [14]. IL-4, IL-10, and IL-13 also up-regulate
IL-1ra expression in LPS activated macrophages [14]. IL-1ra is a competitive inhibitor of
IL-l α and IL-lβ, further reducing inflammation [14].
3.0.3 IFNγ and Lipopolysaccharide
IFNγ is an important cytokine for the activation and maturation of CD4+ T lymphocytes
and macrophages. When IFNγ binds to the interferon gamma receptor (IFNGR), MHCII is
significantly up-regulated on macrophages as well as epithelial and endothelial cells [54].
IFNγ can be produced by both innate and adaptive immune cells including: natural killer
cells, CD8+ cytotoxic T cells, CD4+ T helper type 1 cells [76]. Activation with IFNγ
will cause macrophages to produce inflammatory cytokines and chemokines to help fight
infection. Additionally, IFNγ up-regulates the expression of p21, a cell cycle growth in-
hibitor [36]. The expression of p21 slows down cell growth and activates proteins such
as caspases, which trigger apoptosis in activated macrophages [36]. Without the upregu-
lation of p21 and inhibition of the cell growth cycle, these macrophages would continue
to propagate. Many inflammatory molecules produced by M1 macrophages are cytotoxic
to the cell. If these macrophages were damaged and continued to propagate unchecked,
this would lead to a population of immune cells that are less apt at warding off infections
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against cancer or invading pathogens.
Secretory products can be used to identify a macrophage’s state of activation (i.e. M1
or M2). Secretory products used to identify M1 macrophages are suppressor of cytokines
signaling proteins (SOCS), inducible nitric oxide synthase (iNOS), IL-12, or proteins with
chemokine motifs such as chemokine ligand (CXCL) 9, CXCL10, and CXCL11 [3, 76].
SOCS3 plays an important role in prolonging inflammatory responses and preventing IL-
4 from activating the anti-inflammatory responses [5, 36, 76]. CXCL9, CXCL10, and
CXCL11 all bind to the CXCR3 receptor on natural killer (NK) cells, CD8+ T cells, and
CD4+ T cells resulting in the priming of these cells for inflammatory immune response
[76]. When macrophages produce iNOS the enzyme reacts with L-arginine to make nitric
oxide (NO), which has an anti-microbial and anti-fungal effect [76]. The processes acti-
vated by IFNγ and LPS are associated with intense tissue damage and therefore have to
be tightly controlled in order to limit the extent of the damage [71]. In addition to high
levels of MHCII expression, M1 macrophages also express co-stimulatory molecules that
can activate CD4+ helper T cells in order to help target the infection and limit the scope of
damage [71].
IFNγ signaling
Macrophages require both IFNγ and LPS for full activation [36]. IFNγ must bind to the
IFNGR on the macrophage’s extracellular membrane, and this leads to the activation of
the Jak-Stat signaling pathway (Figure 1) [52]. First, Jak1 and Jak2 autophosphorylate and
transphosphorylate, which creates a binding site for Stat1 [52]. This action allows Stat1
to translocate to the nucleus and bind to IFNγ-response elements, which up-regulates the
necessary genes [61]. Some of the response elements involved are the gamma activation
sequence (GAS), interferon response factor 1 (IRF1), NOD like receptor C5 (NLRC5), and
class II transactivator (CIITA). The binding of STAT1 to the GAS stimulates production of
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IRF1 (Figure 1) [61]. IRF1 can also bind to the GAS to upregulate the CIITA [1, 61]. The
CIITA will bind to the SXY module.
The SXY module has three major parts: X1 which binds the RFX complex, X2 which
binds CREB or ATF1, and Y which binds NFY (Figure 1G) [44]. All parts of this module
are required to express MHCII. Upstream of the SXY module is the MHCI regulatory
complex [57]. This complex is made of two parts: the interferon consensus sequence (ICS)
and enhancer A [57]. The ICS contains the IFN-stimulated response element (ISRE) and
Region I. Enhancer A is made of Regions I and II. See section 3.0.4 for a more detailed
description of these regions.
One of the ultimate endpoints of the IFNγ signaling pathway is the upregulation of
MHCI and MHCII. The upregulation of MHC molecules allows macrophages to present
antigen to B cells and T cells. The IFNγ signaling pathway is important for controlling a
macrophage’s antibacterial and antiviral responses [36].
LPS and TLR4 signaling
Macrophages and dendritic cells have many ways to recognize pathogens, and pattern
recognition receptors are an important part of this recognition system [6]. The family
of toll like receptors (TLRs) are important for a macrophage’s recognition of pathogens
[6, 10]. Toll like receptor 4 (TLR4) binds LPS, and according to Bosisio et al. [6], the pres-
ence of IFNγ increases the expression of TLR4. Activation of a TLR has been shown to
upregulate many pathways, including the NF-κB pathway [10]. Upregulation of the NF-κB
pathway will result in the release of pro-inflammatory cytokines such as IL-1, IL-6, IL-8,
and TNF-α [10].
When LPS binds to the TLR4, it forms a complex with MD-2 [50]. MD-2 physically
associates with TLR4 to enhance the signaling of the NF-κB pathway [59]. CD14 also
works to boost NF-κB signaling by TLR2 [50, 59]. CD14 binds LPS and transfers the
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Figure 1: IFNγ Pathway and MHC presentation schematic. A) IFNγ binds to the IFNGR.
B) IFNGR1 and IFNGR2 come together causing Jak subunits 1 and 2 to move together and
stat1 subunits to bind. C) Stat1 subunits dimerize and move through the cytoplasm and into
the nucleus. D) Stat1 binds to the GAS, which activates genes for IRF1. E) Stat1 binds to
GAS and upregulates NLRC5 genes. F) IRF1 binds to a GAS site and upregulates CIITA
genes. G) RXR/RAR genes bind to region II and NFκB subunits bind to region I to form
enhancer A while IRF1 binds to the ISRE to complete the MHCI regulatory complex. This
complex upregulates the genes required for the CIITA to bind the SXY module and increase
MHCI and MHCII. H) Independent of CIITA, the NLRC5 can enhance genes that will
upregulate MHCI expression only. This exact mechanism is still being defined. Information
for figure taken from references [8, 11, 17, 22, 26, 36–38, 44, 52, 55, 57, 61, 63, 69]
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molecule to the TLR4-MD2 complex so it can activate the proper pathways [50]. TLR4 and
CD14 have broader specificity than other immune receptors so they are able to recognize
molecules of LPS from different strains of bacteria [50]. This flexibility allows the immune
system to use the same receptors to target many strains of bacteria quickly. Without the
ability to respond to LPS, macrophages would not be able to effectively clear Gram negative
organisms from the body.
Binding of LPS causes MD-2 and TLR4 to form a stable heterodimer, which facili-
tates the signaling of TLR4 [50] (Figure 2). After TLR4 heterodimerizes, the Toll/IL-1R
homology (TIR) domains attached to TLR4 will bind the TIR domains of myeloid differ-
entiation factor 88 (MyD88) [64]. MyD88 is a critical adapter protein that is necessary
for the function of nearly all TLRs [20]. Binding of MyD88 creates a docking site for IL-1
receptor-associated kinases (IRAK) [20, 29]. IRAKs 1, 2, and 4 are necessary for activating
the NF-κB pathway [20]. IRAK binds tumor necrosis factor receptor associated factor 6
(TRAF6) and the transforming growth factor beta-activated kinase 1 (TAK1), which forms
a complex with several other adapter proteins and activates the inhibitor of nuclear factor
κ-B kinase (IKK) complex [20, 39]. The IKK complex consists of IKKα, IKKβ, NFκB,
and IκB [39]. When TAK1 binds the IKK complex, IKKα and IKKβ phosphorylate IκB
causing NFκB to dislocate and translocate into the nucleus. At the same time, a mitogen-
activated protein kinase (MAPK) cascade is initiated resulting in AP-1 activation [29, 39].
AP-1 is a transcription factor that enhances the transcription of genes for receptors like
MHCII in macrophages, T cells, and NK cells [8, 56]. In addition to inflammatory cy-
tokines, the TLR4 pathway produces type I IFNs to induce the production of IL-10 as a
means to ensure that inflammation is controlled and inflammatory cytokines do not destroy
surrounding healthy tissues [27].
TLR4 can induce two pathways: the MyD88 dependent pathway and the TRIF-
dependent pathway [20, 29]. The MyD88 pathway was described above. The TRIF path-
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way begins with TRAF3 binding to MyD88 during TLR4 dimerization [29]. Next, TRAF3
is degraded, which signals the TLR4 complex to translocate into the cytoplasm and activate
TAK1 [29]. Then TRIF recruits TRAF6 and TAK1 for NFκB and MAPK activation, simi-
lar to the MyD88 dependent pathway [29]. TRIF also recruits IKKε to phosphorylate IRF3,
causing it to translocate to the nucleus so transcription of IFNγ genes can commence [29].
It should be noted that this pathway in NK cells and Th1 cells will result in production of
IFNγ. However, macrophages do not seem to produce IFNγ but instead produce inflamma-
tory cytokines like IL-12 and IL-18 [56]. The production of IL-12 and IL-18 causes nearby
NK and Th1 cells to increase production of IFNγ, causing macrophages to increase their
response to the surrounding threat [56]. Both the MyD88 and TRIF dependent pathways
are necessary for successful production of inflammatory cytokines and MHCII expression
[29].
3.0.4 Major Histocompatibility Complex I and Major Histocompati-
bility Complex II
Murine macrophages communicate with B cells and T cells via major histocompatibility
complex class I (MHCI) and major histocompatibility complex class II (MHCII) molecules
[25]. Both molecules are needed for successful immune regulation, but each molecule has
a different role in regulating cells.
MHCI expression and signaling
MHCI is expressed constitutively on all nucleated cells [23]. When an internal threat is
detected, MHCI is used to present internal antigens to antigen presenting cells (APCs) [23,
41]. CD8+ cytotoxic T cells recognize the peptide antigens placed on the MHCI receptor
on host cells and respond appropriately to destroy the infected cells [23]. Natural killer
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Figure 2: TLR4 receptor pathway. When LPS binds the TLR4 receptor, it forms a stable
complex with MD-2 allowing the TIR domains to bind adapter protein MyD88. MyD88
then binds IRAK and TRAF6, which dissociate into the cytoplasm. At this point TRAF6
forms a complex with TAK1 and activates MAPK so it can translocate to the nucleus to bind
AP-1 and upregulate MHCII genes. TRAF6 can also phosphorylate the IKK complex. The
IKK complex then phosphorylates the IκB, which is tagged with ubiquitin and degraded
by the proteasome. Degradation of IκB frees NFκB and MAPK to translocate into the nu-
cleus and act as transcription factors in order to produce inflammatory cytokines. This is
referred to as the MyD88 dependent pathway (solid black arrows). The dotted arrows refer
to the TRIF dependent pathway. When this is activated, the TLR4 receptor dissociates from
the membrane and is engulfed in an endosome. Then TRIF activates IKKε to phosphory-
late IRF3, causing it to translocate to the nucleus and induce transcription of IFNγ genes.
Information for figure taken from references [16, 20, 29, 39, 46, 50, 64].
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(NK) cells can be inactivated by MHCI in order to control non-specific immune reactions
[41]. NK cells also recognize the presence or absence of MHCI in order to differentiate
between cells that are self, non-self, or modified self [53]. This discrimination between self
and non-self allows NK cells to target unrecognized cells for destruction [53]. Therefore,
constitutive MHCI expression is necessary for the maintenance of the body’s tissues.
The MHCI regulatory complex is composed of three main elements: region I, region
II and the IFN stimulated response element (ISRE) (Figure 1). Region I contains the NFκB
binding sequence, while region II contains sites for retinoic acid receptors (RARs) and
retinoid x receptors (RXRs) [37, 57]. RXRs and RARs dimerize to become response ele-
ments that enhance transcription and induce a variety of transcription factors such as AP-2
[57]. Segars et al. [57] demonstrated that retinoic acid can induce NFκB genes. Regions
I and II of the MHCI regulatory complex make up enhancer A and together these regions
help guide MHCI transcription. The ICS is comprised of region I and the ISRE [37]. The
ICS controls and enhances the regulation of IFN-induced MHCI gene expression, while
the ISRE functions in transcription regulation [55, 63].The ISRE also controls IFN regu-
latory factor 1 (IRF1), which functions as a transcription factor in the JAK/STAT pathway
[22, 37]. Downstream of the MHCI regulatory complex is the SXY module, which is re-
quired for CIITA and NLRC5 binding [38, 69].
MHCI and MHCII are mainly induced by the IFN family of cytokines and CIITA
is a master regulator of both MHCI and MHCII expression [17, 26]. MHCI can be ex-
pressed independently of MHCII, but MHCI expression is also increased when MHCII is
upregulated because the pathways share the same regulatory promoter (the SXY module)
(Figure 1) [38, 69]. MHCI expression is controlled by NOD-like receptors (NLRs). NLRs
are a family of pattern recognition receptors that activate or deactivate signaling pathways
important for immunity [11]. The NLR that controls MHCI expression is NLRC5 [11].
NLRC5 has been shown to be specific for MHCI alone, whereas CIITA can activate
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both MHCI and MHCII [38]. Neerincx et al. [44] report that NLRC5 can bind to the SXY
module similar to CIITA, and coexpression of NLRC5 and CIITA has an additive effect
[44]. NLRC5 has been found in both the cytoplasm and the nucleus, suggesting it is a
regulatory factor [11, 34]. Cui et al. [11] found evidence that NRLC5 acts in the cytosol to
negatively regulate the NFκB pathway and the type I IFN signaling pathway. NLRC5 binds
to the IKKα and IKKβ subunits to block their phosphorylation [11]. Additionally, Cui et
al. [11] performed functional gene reporter assays which showed NLRC5 can successfully
inhibit LPS- and TRIF-induced NFκB. The results of Cui et al. suggest that NLRC5 acts as
an antagonist as well as a transcription factor. These results help to link the NFκB, TLR4,
and IFNγ pathways (Figures 1 and 2). NLRC5 appears to be important for regulating
constitutive expression of MHCI, however NLRC5 was only discovered recently and the
regulation of this pathway is still in the process of being defined.
MHCII signaling and expression
MHCII is only expressed constitutively on antigen presenting cells (APCs) such as
macrophages, dendritic cells, and B cells [54]. MHCII presentation is not only required
for APC function, but T cell maturation as well [36, 54]. When IFNγ binds to its surface
receptor, MHCII expression is significantly increased [36, 54]. IL-4 and IL-13 can also in-
crease MHCII expression on human B cells and macrophages, while murine macrophages
do not increase MHCII expression in the presence of IL-13 [54]. However, IL-10 has been
shown to significantly reduce the number of MHCII molecules present on the cell’s surface
[24].
MHCII molecules present peptide antigen to CD4+ helper T cells [24, 54]. Expression
of MHCII molecules is under the regulatory control of the MHCII transactivator (CIITA)
[65, 67]. Without the CIITA, neither constitutive nor IFNγ induced MHCII would be pos-
sible [36, 65]. Transcription of CIITA is upregulated by cytokines IFNγ, and IL-4 as well
as endotoxin LPS [67]. IL-10, TGF-β, and nitric oxide cause CIITA transcription to be
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down regulated [67]. If transcription and translation of MHCII molecules were not tightly
controlled, then the immune system would not function properly [47]. Failure to regulate
MHCII expression can lead to various autoimmune diseases such as multiple sclerosis or
acquired immune deficiency syndrome dementia complex [47].
3.0.5 The Aryl Hydrocarbon Receptor
Classical AhR signaling
The AhR is located in the cytosol of the cell and is stabilized by a number of proteins (Fig-
ure 3) [7, 62]. When the AhR is not bound to its ligand, it is stabilized in the cytoplasm
by heat shock protein 90 (HSP90), HSP90’s co-chaperone p23, and Hepatitis B Virus X-
associated protein-2 (XAP2) [7, 16]. If an exogenous ligand binds to the AhR, it translo-
cates into the nucleus via importins, and undergoes a conformational change in its PAS A
domain. Inside the nucleus, the AhR forms a complex with the AhR nuclear translocator
protein (Arnt) allowing it to bind xenobiotic-response elements (XREs), where it serves as
a transcription factor [28, 45, 70]. The AhR can also be repressed by the AhR repressor
(AhRR) [2]. The AhRR can also bind to Arnt without the transactivation of Arnt. The
AhRR-Arnt complex can then bind to XREs to compete with AhR-Arnt dimers [2]. After
transcription, AhR is released from the DNA and exported back to the cytoplasm to be
degraded by the ubiquitin-mediated 26S proteasome pathway [28].
When the AhR complex binds the XRE, several genes are activated. The CYP pro-
moter is responsible for activating the CYP1 gene (a cytochrome p450 enzyme) [2, 28, 60].
The CYP1 gene has three components (CYP1A1, CYP1A2, and CYP1B1) referred to as
phase I xenobiotic metabolizing enzymes [2]. The AhR has been shown to interact with
genes for several pathways including: NFκB, retinoblastoma protein-1, estrogen receptors,
androgen receptors, thyroid hormone receptors [2, 7, 28].
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Figure 3: AhR activation pathway. A) When a suitable AhR ligand enters the cell, it binds
to the AhR, XAP2 dissociates and the rest of the complex migrates through the importin
and into the nucleus. B) Once inside, the AhR ligand complex disassociates from HSP90
and p23 to form a dimer with Arnt (C). D) The AhR/Arnt complex can bind XREs to
turn on genes such as CYP1A1, CYP1A2, and CYP1B1. E) The AhR can be repressed
by the AhRR. If the AhRR complexes with Arnt then it can also bind to XRE sequence,
competitively inhibiting the AhR/Arnt complex. F) Once transcription is completed, the
AhR dissociates from the DNA and exits the nucleus. G) Once in the cytosol, the AhR
is degraded by the ubiquitin mediated 26S proteasome pathway. Information from figure
taken from references [2, 7, 16, 28, 43, 45]
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NFκB pathway
Dendritic cells and macrophages have been the primary model for studying the effect of
the AhR on the innate immune system. Both are phagocytic cells capable of producing
cytokines for communication with other leukocytes, and both can present antigen to lym-
phocytes [30]. Cells that are defective in specific receptors like the AhR or NFκB regula-
tory proteins can be used to define these pathways in vitro. The NFκB pathway is one of
the most well studied pathways because it has many possible interactions and feeds into
many pathways. NFκB participates in cell cycle regulation, cell differentiation and many
immune responses [16]. The TLR4 pathway can stimulate the NFκB pathway (Figure 2)
[73].
NFκB has five major transcription factors: RelA, RelB, c-Rel, NFκB1, and NFκB2
[58]. NFκB1 and NFκB2 are cleaved to their p50 and p52 forms [58]. Then p50 and p52
will form dimers with inhibitor of κB (IκB) proteins. This complex will sit in the cytosol
until TRAF6 activates IKK complex [64]. Then the IKK complex (composed of IKKα,
IKKβ, and IKKγ) phosphorylates IκB allowing the NFκB dimers to leave the cytosol and
enter the nucleus, while IκB is tagged with ubiquitin and degraded by the proteasome in
the cytosol [46]. Once in the nucleus, NFκB acts as a transcription factor to upregulate
several processes, such as inducing production of pro-inflammatory cytokines.
Vogel et al. [73] used human dendritic cells to demonstrate the relationship between
the NFκB pathway and the AhR pathway. The AhR directly interacts with RelB (an NFκB
subunit) and the suppression of this interaction causes decreased maturation of bone mar-
row derived dendritic cells [73]. NFκB signaling enhances AhR regulated genes, and the
absence of the NFκB pathway reduces LPS-induced AhR signaling [73]. Vogel et al. [73]
also showed that one of the NFκB binding sites for the AhR was responsive to LPS. These
results demonstrate that the TLR4 pathway and the NFκB pathway can influence AhR
genes. Vorderstrasse et al. [75] demonstrated that dendritic cells treated with TCDD in the
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absence of antigen showed an increase in MHCII expression. The dendritic cells did not
show an increase in MHCII after stimulation with antigenic tumor cells [74]. While these
data were not intuitive at first glance, when combined with the observations of Vogel et
al. [73], they further support the notion that the NFκB pathway is connected to the AhR
pathway because MHCII expression is induced by both LPS (TLR4 pathway) and IFNγ
(JAK/STAT pathway) (Figures 1 and 2).
Kimura et al. [33] demonstrated that AhR knock out mice were more sensitive to
LPS and LPS-induced toxicity. The authors also found that LPS induces AhR expression
in macrophages [33]. Macrophages from AhR knock out mice produced more proinflam-
matory cytokines like IL-6 and TNF-α, however, the macrophages were unable to produce
IL-10 [33]. The AhR forms a complex with Stat1 and NFκB, further indicating that the
AhR interacts with many pathways [33]. Kimura et al. [32] also found that AhR knock out
mice exposed to Listeria monocytogenes were more likely to become infected than wild
type mice [32]. AhR knock out macrophages showed decreased rates of cell survival and
decreased reactive oxygen species production, indicating the AhR is necessary for protect-
ing macrophages from infection [32].
AhR ligands and antagonists
The Aryl Hydrocarbon Receptor (AhR) was originally discovered when investigating re-
ceptors for environmental contaminants [45]. The AhR is also known as the dioxin receptor
because 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can bind the AhR and activate it [43].
Since its discovery, the AhR has been implicated in oxidative stress, cell cycle regulation,
apoptosis and several processes of immune cell function [43, 45].
Because the AhR is involved in many pathways, there has to be a number of ways
to study it. Some scientists have studied the AhR in vivo by breeding knock out mice,
however, offspring of female mice with knocked out AhR genes have not survived past
20
five weeks old in environments where germs are present [33, 62]. It is suspected that these
mice may not be able to survive due to the inability to mount an immune response by
macrophages or dendritic cells [33]. Suitable mice have to be made by crossing female
mice heterozygous for the AhR with male mice that are AhR deficient [62]. The AhR can
also be studied in vitro by using AhR knock out cells or AhR antagonists.
The AhR is capable of binding a wide variety of ligands, which can make studying the
receptor’s effect on the cell difficult [31, 79]. The AhR can bind several types of natural
and non-natural ligands. The best characterized non-natural classes of AhR ligands are
halogenated aromatic hydrocarbons (HAH) and polycyclic aromatic hydrocarbons (PAHs)
[15, 79]. HAHs are more stable and tend to be more potent than PAHs [15]. The high stabil-
ity of HAHs allows for a higher binding affinity (range pM to nM), while PAHs have lower
binding affinities (range nM to µM) [15]. The best characterized natural classes of ligands
tend to come from plants, such as flavonoids, carotinoids, and curcumin [15]. Humans are
exposed to natural AhR ligands far more often than non-natural ligands, however using
non-natural ligands to understand the pathway of the AhR can facilitate the understanding
of less stimulatory natural ligands or antagonists.
AhR antagonists can be used to study the effects of the AhR and since the AhR can
bind a diverse set of ligands, the number of antagonists are just as diverse. At lower concen-
trations (nM), antagonists will inhibit the AhR, but at higher concentrations (µM) some an-
tagonists can exhibit a stimulatory effect on the AhR [78]. Some antagonists can also bind
the estrogen receptor and influence the estrogen pathway [31]. Kim et al. [31] screened
roughly 10,000 compounds in search for an antagonist that binds the AhR without simulat-
ing it or activating the estrogen pathway. From this screening they found 2-Methyl-2H-
pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) did not
have agonist effects even at 100µM, nor did CH-223191 show stimulation of the estro-
gen receptor [31]. CH-223191 was compared against other known antagonists like flavone,
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reservatrol, and α-naphthoflavone. CH-223191 was found to be the most effective antago-
nist for inhibiting TCDD [31].
Some AhR antagonists, such as flavonoids, have cytotoxic effects at high concentra-
tions, but CH-223191 did not exhibit this property even at 100µM [31, 78]. While CH-
223191 is an effective competitive antagonist against TCDD (an HAH), it is less effective
against β-naphthoflavone (BNF) (a PAH-like molecule) [79]. Zhao et al. [79] co-incubated
guinea pig intestinal cells with maximally inducing concentrations of either TCDD (1nM)
or BNF (1µM) and increasing concentrations of CH223191. While TCDD activation was
inhibited in a dose dependent manner, BNF activation was only reduced by 30% for the
highest concentration of CH223191 [79]. Zhao et al. [79] also found that CH-223191 in-
hibits AhR-dependent reporter gene expression in cells treated with varying concentrations
of TCDD, but this effect was less pronounced when CH-223191 and BNF were tested to-
gether. The group also tested a number of HAHs and PAH-like molecules and found this
same trend. These results suggest that CH-223191 is a well suited antagonist for TCDD or
other HAHs, but it is not effective against agonists like BNF or similar PAH-like molecules




J774A.1 murine macrophages (ATCC, Manassas, VA) are derived from reticulum cell sar-
comas of female BALB/cN mice. The cells are semi-adherent so they were propagated
in 50mm plastic petri dishes and were incubated in 5% carbon dioxide at 37oC in a wa-
ter jacketed incubator. Cells were passaged three to four times weekly in a mixture of
Dulbecco’s Modified Eagle’s Medium (DMEM), 10% fetal bovine serum (FBS), and 1%
streptomycin/penicillin. Cells were passaged at 80% confluency and subcultured at a ratio
of 1:6. Confluency was estimated by viewing cells under a microscope and assessing the
approximate amount of cells covering the dish. For example, cells are considered 50%
confluent when half of the dish is covered in cells. DMEM, petri dishes, and FBS were
purchased from Fisher Scientific (Pittsburgh, PA).
RAW 264.7 murine macrophages (ATCC, Manassas, VA) were derived from Abelson
murine leukemia virus-induced tumors of male BALB/c mice. The cells were propagated
in the same manner as the J774A.1 macrophages.
4.0.2 Cell Polarization Treatments
Macrophages were grown to 60% confluency and treated with cell polarization treatments.
Cells were polarized to the inflammatory state (M1) with LPS (100 ng/mL), IFNγ (20
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ng/mL) or LPS and IFNγ together. Cells were polarized to the anti-inflammatory state
(M2) with IL-4 (20ng/mL), IL-10 (10ng/mL), or IL-13 (10ng/mL) alone. All polarization
treatments were performed 24 hours prior to cell viability or flow cytometry experiments.
IL-4, IL-10, IL-13, and IFNγ were purchased from Pepro Tech (Rocky Hill, NJ) and LPS
from E. Coli 0111:B4 was purchased from Chondrex Inc (Redmond, WA).
4.0.3 Cell Counting and Viability Experiments
Cells were harvested when they reached approximately 80% confluency and spun in the
centrifuge at 153 relative centrifugal force (RCF). Cells were resuspended in complete
growth medium and mixed throughly. Then 10µL of cell suspension was mixed with 10µL
of trypan blue (Fisher Sciences, Pittsburgh, PA) and loaded into a hemocytometer (Figure
4). Cells that absorbed the dye appeared blue, while cells that excluded the dye appeared
translucent. All blue cells were counted and recorded as dead while the translucent cells
were recorded as alive. Four corner boxes were counted and the following formula was




Total Viable Cell Count
4 Grids Counted
× Dilution Factor × 104 (4.1)
An estimate of cell viability was calculated from the following equation:
Average Number of Viable Cells
Average Live Cells + Average Dead Cells
× 100 = %Viable Cells (4.2)
Cell viability was calculated for each sample and statistical analysis was performed in
SigmaPlot 13.0 (Systat Software Inc., San Jose, CA). All conditions were tested in tripli-
cate.
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Figure 4: Hemocytometer counting example. The red line represents one box. Blue circles
represent dead cells while white circles represent living cells. Live and dead cells were
counted and recorded. The four corner squares were counted and the cell count equation




Cells were grown to approximately 60% confluency and then treated with the appropriate
cytokines. After 24 hours, cells were harvested and counted with a hemocytometer. Ap-
proximately 1.5-2 million cells from each treatment were placed in 1.5 mL microcentrifuge
tubes and washed twice with 1% Bovine Serum Albumin (BSA). All washes were spun at
153 RCF for 5 minutes at 4oC. Then cells were fixed with 4% paraformaldehyde for 20
minutes at room temperature. Next, all samples were washed with 1% BSA and permeabi-
lized with 0.1% saponin at room temperature for 15 minutes. Cells were then blocked for
30 minutes with 3% BSA+ 0.1% saponin and washed twice with 1% BSA+ 0.1% saponin.
Following the washes, cells were stained with Anti-mouse AhR primary antibody conju-
gated with PE (Novus Biologicals, Littleton, CO) in 100 µL of 3% BSA for 30 minutes at
4o C. Antibodies were diluted at a 1:300 ratio. Following staining, cells were washed once
with 1% BSA+ 0.1% saponin, resuspended with 500µL of 10% FBS+0.1% sodium azide
in ice cold PBS and analyzed by flow cytometry on an Accuri C6 Flow Cytometer. BSA,
PBS, and saponin were purchased from Fisher Scientific (Pittsburgh, PA).
Cell Surface Antigen Staining
Cells were grown to approximately 60% confluency and treated with the appropriate cy-
tokines. After 24 hours, cells were harvested and counted with a hemocytometer. Approx-
imately 1.5-2 million cells from each treatment were placed in 1.5 mL microcentrifuge
tubes and washed twice with 1% BSA. All washes were spun at 153 RCF for 5 minutes at
4oC. Cells were then blocked with 3% BSA for 30 minutes at room temperature and then
washed twice with 1% BSA. Next cells were stained for MHC class I with Anti-mouse H-
2Dd primary antibody conjugated with Fluorescein isothiocyanate (FITC) (Biolegend, San
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Diego, CA). Cells were stained for MHC class II with Anti-mouse I-Ad primary antibody
conjugated with Alexa Fluor 647 (Biolegend, San Diego, CA). Antibodies were diluted in
3% BSA at a 1:300 ratio. Cells were incubated at 4oC for 30 minutes and then washed
once with 1% BSA. Cells were then resuspended with 500µL of 10% FBS+0.1% sodium
azide in ice cold PBS and analyzed by flow cytometry on an Accuri C6 Flow Cytometer
(BD Biosciences, San Jose, CA).
Cell Viability Analysis via Annexin V and Propidium Iodide
While cell death can be detected with trypan blue, this dye alone is insufficient to assess
the stages of cell death. Trypan blue is a cationic dye that is actively excluded from the cell
membrane if cells are alive [12]. When total cell death occurs, the cell membrane can no
longer actively exclude the dye and the cell appears blue to the naked eye. However, this
only shows cells in the latest stages of cell death. The early stages of apoptosis must be
detected by annexin V or cell death antibodies.
The cellular plasma membrane has asymmetric distributions of phospholipids
throughout its inner and outer layers [13]. Molecules like phosphatidylcholine and sph-
ingomyelin are located on the outer bilayer of living cells, while phosphotidylserine is
located on the inner bilayer. When a cell begins its cycle of apoptosis, the cell’s plasma
membrane loses its asymmetry and phosphotidylserine is exposed on the outer bilayer.
Phosphotidylserine exposure acts as a signal for macrophages to phagocytose and dispose
of the cell [12, 13, 72]. Annexin V is an anticoagulant that selectively binds negatively
charged phosphotidylserine and thus allows for the identification of early and late stage
apoptotic cells [12]. Propidium iodide (PI) is a cationic fluorescent dye that binds nuclear
DNA [13]. When fluorochrome conjugated-annexin V is combined with PI, necrosis can
be distinguished from apoptosis [13].
J774A.1 or RAW264.7 macrophages were grown until they reached approximately
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60% confluency. Cells were treated with the appropriate cytokines for 24 hours, counted
and 1.5-2 million cells were placed in 1.5mL microcentrifuge tubes. Cells were washed
twice with cell staining buffer (Biolegend) and then resuspended in 100 µL of annexin V
binding buffer (Biolegend). All washes were spun at 153 RCF for 5 minutes at 4oC. Next, 5
µL of Phycoerythrin (PE) conjugated annexin V stain and 10 µL of PI were added to each
sample. Cells were resuspended and incubated for 15 minutes at room temperature. After
the incubation, 400 µL of annexin V Binding Buffer was added to each tube and samples
were analyzed by flow cytometry on an Acuri C6 Flow Cytometer (BD Biosciences, San
Jose, CA).
4.0.5 Aryl Hydrocarbon Anatagonist Treatment
The aryl hydrocarbon antagonist (AhRa) (CH-223191) was dissolved in pure Dimethyl Sul-
foxide (DMSO) at a concentration of 100 mM and stored in glass vials at −20oC until use.
The appropriate working dilution for the AhRa was determined by concentration-response
analysis to be 30µM. To make a working dilution, the AhRa was thawed and an appropriate
amount of PBS was added to the glass vial in order to make a concentration of 30mM. A 10
fold dilution was performed into PBS to lower the concentration of DMSO to 3.0% (con-
centration of 3mM AhRa). A final 100 fold dilution was performed by addition of AhRa
into the medium ensuring the end concentration of DMSO was 0.03%, and giving a final
concentration of 30µM AhRa. After the AhRa was added, the dishes were gently rocked
back and forth to ensure the even dispersal of the antagonist. Then the cells were incubated
at 37oC for one hour to allow the AhRa to bind to the AhR. Following the one hour incuba-
tion, the cells were treated with cytokines for 24 hours and then the samples were analyzed
by flow cytometry on an Accuri C6 Flow Cytometer. The AhRa was purchased from EMD




Histogram analysis was performed in MATLAB (Mathworks, Natick, MA). Each his-
togram was generated and the isotype control histogram was subtracted from the exper-
imental histogram to generate the percentage of cells that stained positively (percent pos-
itive) (Figure 5). The percent positive cell number was calculated using the methods of
W. Roy Overton [48]. In order to ensure the MATLAB code was functioning as well as a
commercial product, the MATLAB code was validated against data from FCSExpress4.0.
Differences within a half percent were considered to be of acceptable tolerance. This analy-
sis was completed for every experimental condition in triplicate and then statistical analysis
was performed in Sigma Plot 13.0 (Systat Software Inc., San Jose, CA).
4.0.7 Annexin V Gating Analysis
Annexin V gating analysis was performed using Cytospec Software from Purdue University
Cytometry Laboratories (http://www.cyto.purdue.edu/Purdue_software).
Gating was based on the methods of Wlodkowic et al. (2009). Because propidium iodide
and annexin V will only stain unhealthy cells, unstained cells were used to help define
where to set the gates (Figures 37-40 in Appendix B). A second set of cells were heat
shocked at 95oC for 30 minutes in order to help gate dead cells. Cells stained with annexin
V alone are considered early apoptotic, while cells that stain with PI alone are considered
necrotic [12]. Cells that stain with neither annexin V or PI are considered alive, while
cells that stain with both annexin V and PI are considered to be in late apoptosis [12]. The
heat shocked cells were gated for early apoptosis, late apoptosis, and necrosis. The breed
gates function was used to apply all gates to subsequent experimental conditions (Figure
6). Data were then compiled into SigmaPlot 13.0 (Systat Software Inc., San Jose, CA) and
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Figure 5: FCSExpress v. MATLAB processing. The methods of W. Roy Overton [48] were
used to generate MATLAB code and were compared against data generated in FCSExpress
4.0. This was necessary in order to ensure the code was functioning as well as commercial
software. Part A shows a representative image generated in FCSExpress 4.0. Part B shows
a representative image generated in MATLAB. While the counts on the Y axis are differ-
ent, the percent positive numbers are within a half of a percent and the graphs are almost
identical in appearance.
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Figure 6: Representative figure generated in Cytospec Software. Dot plot was gated for




4.0.8 Fold Change Analysis
All fold change analyses were performed in Microsoft Excel. First, experimental sample
groups were averaged and the fold changes were calculated with the following formula:
Fold Change =
average percent positive of experimental sample
average percent positive of control sample
(4.3)
All experimental groups were normalized with respect to the control sample.
4.0.9 Statistical Analysis
For each experiment, cells were grown from frozen stock and passaged until there were
approximately 55-60 million cells. Then groups of 6-9 million cells were treated with the
appropriate cytokines and counted the next day. After counting, 1.5-2 million cells from
each experimental group were placed in a 1.5mL centrifuge tube. Each experimental group
had a total of 3 samples with 1.5-2 million cells each. Results from the 3 samples were
averaged together and the average percentage of positive cells was called N=1. For an
experiment with N=3, this process was repeated twice.
Statistical significance was determined using one way ANOVA and the groups were
compared with multiple comparisons vs. control group via the Holm-Sidak method
(SigmaPlot 13.0, Systat Software Inc., San Jose, CA). All statistical comparisons were
made against the control unless otherwise noted.
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Results
5.0.1 The effects of cytokine treatment on Raw264.7 and J774A.1 cells
Raw264.7 cells were treated for 24 hours with cytokines IL-4, IL-10, IL-13, and IFNγ
or endotoxin LPS in order to get a baseline for MHCI and MHCII expression (Figure
7). MHCI expression was not significantly different from untreated (M0) cells for any
experimental condition. MHCII was significantly increased when cells were treated with
LPS, IFNγ, or LPS and IFNγ together (Figure 7). Cells treated with IL-4, IL-10, and IL-
13 showed no difference in MHCI and MHCII expression when compared with untreated
macrophages.
J774A.1 cells were also treated for 24 hours with cytokines and LPS in order to obtain
a baseline for MHCI and MHCII expression (Figure 8). There was no significant change
in MHCI or MHCII expression between any of the treatment groups and the control. See
Appendix A for gating strategy referencing Figures 7-13.
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5.0.2 Confirmation of the expression of the Aryl Hydrocarbon Recep-
tor in Raw264.7 and J774A.1 cells
Both cell lines were stained for the presence of the AhR and both cell lines stained positive
for the AhR. The Raw264.7 cell line showed significant increases in AhR in IL-10, LPS
and the LPS & IFNγ treated groups (Figure 9). Although not statistically significant, the
IFNγ treated group showed very low levels of the AhR.
J774A.1 cells showed significant decreases in AhR expression following the IL-4 and
IL-10 treatments (Figure 10). No other groups showed significant differences when com-
pared with the untreated control cells. However, the J774A.1 cells showed more AhR
expression overall compared to the Raw264.7 cells (Figures 9 and 10).
5.0.3 The effects of AhRa on Raw264.7 and J774A.1 cells after cell
polarization.
The optimal amount of AhR antagonist CH-223191 (AhRa) was determined by concen-
tration response analysis in Raw264.7 cells (Figure 11). To identify the effects of AhRa
on MHCI expression, Raw264.7 cells were treated with IL4 and 0, 10, 20, or 30µM of
AhRa. To identify the effects of AhRa on MHCII expression, Raw264.7 cells were treated
with LPS, IFNγ and 0, 10, 20, or 30µM AhRa. The MHCI expression was examined
on M2 cells because MHCI expression was more consistent on IL4-treated cells. MHCII
expression has to be induced by IFNγ or LPS, so M1 cells were also used for this proce-
dure. MHCII is only expressed constitutively at low levels on untreated or M2 polarized
cells. The appropriate amount of antagonist was determined to be 30µM of AhRa because
this concentration showed the most dramatic change of both MHCI and MHCII expres-
sion when compared to untreated cells. While 10µM AhRa showed an increase in MHCI,
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there was no change in MHCII expression. 30µM AhRa provided the greatest change in
both MHCI expression and MHCII expression. Concentrations higher than 30µM were not
examined in order to minimize unintended effects from the antagonist, such as increased
cellular cytotoxicity or unintended simulation of other receptors. Additionally, concentra-
tions of AhRa higher than 30µM would lead to DMSO concentrations that could interfere
with cellular processes.
Following concentration response analysis, Raw264.7 cells were treated with 30uM
AhRa for one hour and then the appropriate cytokines for 24 hours. Following this treat-
ment, MHCI levels showed similar expression levels for all cytokine treated groups (Figure
12). Treatment with AhRa lead to significantly increased MHCII expression for IFNγ and
LPS & IFNγ treated groups. When J774A.1 cells were treated with AhRa there was no
change in MHCI expression (Figure 13). M1 cells showed an increase in MHCII expres-
sion compared to the cells treated with cytokines alone. However, there was no statistical
significance between any of the groups.
Because the experiments for cytokines only and cytokines + AhRa were not performed
at the same time, fold change comparisons were performed in order to directly compare
the results of the studies. Analysis showed that Raw264.7 and J774A.1 cells stained for
MHCI showed no difference between the cytokines without AhRa and the cytokines with
AhRa experimental groups (Figures 14 and 15). For Raw264.7 cells stained for MHCII
expression, there was no change between the M2 cells. Raw264.7 cells treated with LPS
showed a reversal of MHCII expression to M0 levels after treatment with AhRa (Figure
14). The Raw264.7 cells treated with IFNγ or LPS & IFNγ showed partial reversal relative
to the M0 control after AhRa treatment. Two way ANOVA analysis showed that J774A.1
cells treated with IL-10 had a significant increase in MHCII expression after the addition
of AhRa (Figure 15). All M1 J774A.1 cells showed an increase in MHCII expression after
the addition of AhRa (Figure 15). However, only the IFNγ M1 group showed a significant
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increase of MHCII expression. The other M1 groups had too much error to be significant
by two way ANOVA analysis.
5.0.4 Raw264.7 and J774A.1 cell viability by trypan blue
Raw264.7 cells were tested for cell viability after 24 hours of treatment with 30µM AhRa
and cytokines (Figures 16 and 18). Raw264.7 macrophages treated with LPS & IFNγ
showed decreased viability when compared to the untreated macrophages. When cells
were treated with the cytokines and 30µM AhRa, cell viability was increased in the group
treated with LPS and IFNγ. The trypan blue viability was also replicated on J774A.1
cells (Figures 17 and 19). J774A.1 macrophages treated with LPS and IFNγ showed a
statistically significant decrease in cell viability, however, this statistical significance does
not appear to be biologically relevant.
5.0.5 Raw264.7 and J774A.1 cell viability via annexin V and propid-
ium iodide
Raw264.7 cells were tested for cell viability after 24 hours of treatment with cytokines
alone or 30µM AhRa and cytokines. Cells were then stained with annexin V and pro-
pidium iodide and analyzed via flow cytometry as described in Methods. There were no
statistically significant differences between the late apoptotic, early apoptotic, necrotic or
live cell groups for cells treated with only cytokines (Figure 20), however for cells treated
with 30µM AhRa, LPS, and IFNg there was a significant increase in late apoptosis (Figure
22). This data is similar to the trypan blue viability results (Figures 16 and 18). Since
annexin V binds phosphotidylserine (an early indicator of apoptosis) the test is considered
more sensitive than using cationic dyes like trypan blue because it allows dead cells to
be divided into categories of early apoptosis, necrosis, and late apoptosis. The annexin V
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analysis was replicated on J774A.1 cells and there was a statistically significant decrease
in live cells treated with IL-13 and IFNγ (Figure 21). Cells treated with IFNγ and AhRa
showed a significant increase in late apoptosis relative to the live M0 control (Figure 23D).
Cells treated with LPS, IFNγ, and AhRa also showed a significant increase in late apoptotic
cells (Figure 23D). There were no other significant differences present after treatment with
30µM of AhRa (Figure 23).
Fold change comparisons between Raw264.7 cells showed no significant differences
between live and early apoptotic cells before and after the addition of AhRa (Figure 25A
and B). All experimental groups except cells treated with IL-4 showed an increase in
necrotic cells after the addition of AhRa (Figure 25C). Late apoptosis increased after the
addition of AhRa for cells treated with LPS & IFNγ (Fiugre 25D). All experimental groups
were normalized relative to their respective M0 controls. Analysis by two way ANOVA did
not show statistical significance between any groups.
Fold change comparisons for live and early apoptotic J774A.1 cells showed no dif-
ference between the experimental groups (Figure 25A and B). Overall the percentage of
necrotic J774A.1 cells was higher than the Raw264.7 cells (Figures 25 and 24). All
Raw264.7 M1 cells showed an increase in necrosis after the addition of AhRa (Figure
25C). IL-10 treated cells also showed an increase in necrosis after AhRa was added. There
were increases in late apoptotic cells for groups treated with LPS and LPS & IFNγ after
the addition of AhRa (Figure 25D). All experimental groups were normalized relative to
their respective live M0 controls. Two-way ANOVA was performed, however, there was
no statistical significance between any of the samples.
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Figure 7: Raw264.7 cells polarized for 24 hours and stained for MHCI and MHCII. All
treatments were performed 24 hours prior to staining for the presence of MHCI and MHCII.
A) Cells are stained for MHCI. B) Cells are stained for MHCII. * symbol indicates statis-
tical significance compared to the M0 control cells. **=p<0.01, ***=p<0.001. NT= no
treatment. N=3. Cell states (M0, M1, M2) are indicated by light grey, dark grey, and black
as indicated by the key.
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Figure 8: J774A.1 cells polarized for 24 hours and stained for MHCI and MHCII. All
treatments were performed 24 hours prior to staining for the presence of MHCI and MHCII.
A) Cells are stained for MHCI. B) Cells are stained for MHCII. NT= no treatment. N=3.
Cell states (M0, M1, M2) are indicated by light grey, dark grey, and black as indicated by
the key.
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Figure 9: Raw264.7 cells polarized for 24 hours and stained for the aryl hydrocarbon re-
ceptor. All cells were polarized for 24 hours before they were stained for the presence
of the AhR. * symbol indicates statistical significance compared to the M0 control cells.
**=p<0.01, ***=p<0.001. M0 cells are unpolarized cells. N=1. Cell states (M0, M1, M2)
are indicated by light grey, dark grey, and black as indicated by the key.
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Figure 10: J774A.1 cells polarized for 24 hours and stained for the aryl hydrocarbon re-
ceptor. All cells were polarized for 24 hours before they were stained for the presence of
the AhR. * symbol indicates statistical significance compared to the M0 control cells. **=
p <0.01. M0 cells are unpolarized cells. N=1. Cell states (M0, M1, M2) are indicated by
light grey, dark grey, and black as indicated by the key.
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Figure 11: AhRa concentration response of MHCI and MHCII protein levels on Raw264.7
cells. Raw264.7 cells were treated with 0, 10, 20, or 30 uM AhRa for 1 hour followed by
treatment with LPS and IFNγ or IL4 for 24 hours. The next day IL4-treated cells were
stained for MHCI and LPS and IFNγ treated cells were stained for MHCII. N=1.
42
Figure 12: Raw264.7 cells treated with 30uM AhRa then polarized for 24 hours and
stained for MHCI and MHCII. All treatments were performed 24 hours prior to staining
for the presence of MHCI and MHCII. A) Cells are stained for MHCI. B) Cells are stained
for MHCII. * symbol indicates statistical significance compared to the M0 control cells.
***=p<0.001. NT= no treatment. N=3. M0 cells are unpolarized cells. Cell states (M0,
M1, M2) are indicated by light grey, dark grey, and black as indicated by the key.
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Figure 13: J774A.1 cells treated with 30uM AhRa then polarized for 24 hours and stained
for MHCI and MHCII. All treatments were performed 24 hours prior to staining for the
presence of MHCI and MHCII. A) Cells are stained for MHCI. B) Cells are stained
for MHCII. * symbol indicates statistical significance compared to the M0 control cells.
**=p<0.01. NT= no treatment. N=3. M0 cells are unpolarized cells. Cell states (M0, M1,
M2) are indicated by light grey, dark grey, and black as indicated by the key.
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Figure 14: Fold change comparison of Raw cells stained for MHCI and MHCII. Each fold
change comparison was relative to the respective M0 control. Results from figures 7 and
12 are compared against each other (N=3 for all experiments). A) Shows MHCI expression
from both experiments. B) Shows MHCII expression from both experiments.* symbol
indicates comparison to the corresponding M0 control group. **=p <0.01 ,***=p <0.001.
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Figure 15: Fold change comparison of J774A.1 cells stained for MHCI and MHCII. Each
fold change comparison was relative to the respective M0 control. Results from figures
8 and 13 are compared against each other (N=3 for all experiments). A) Shows MHCI
expression from both experiments. B) Shows MHCII expression from both experiments.
* symbol indicates comparison to the corresponding M0 control group. **=p <0.01. +
symbol indicates a statistical difference between the cytokines only and the cytokines +
AhRa treatment groups. + = p <0.05
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Figure 16: Viability of Raw264.7 cells polarized for 24 hours. All treatments were per-
formed 24 hours prior to staining with typan blue and counting on a hemocytometer. The
table contains the average cell counts and average percent viability for all conditions. *
symbol indicates statistical significance compared to the M0 control cells. ***= p<0.001.
NT= no treatment. N=3. M0 cells are unpolarized cells. Cell states (M0, M1, M2) are
indicated by light grey, dark grey, and black as indicated by the key.
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Figure 17: Viability of J774A.1 cells polarized for 24 hours. All treatments were performed
24 hours prior to staining with trypan blue and counting on a hemocytometer. * symbol
indicates statistical significance compared to the M0 control cells. ***=p<0.001. M0 cells
are unpolarized cells. NT=not treated. N=3. Cell states (M0, M1, M2) are indicated by
light grey, dark grey, and black as indicated by the key.
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Figure 18: Viability of Raw264.7 cells treated with 30uM AhRa and then polarized for
24 hours. All treatments were performed 24 hours prior to staining with typan blue and
counting on a hemocytometer. The table contains the average cell counts and average
percent viability for all conditions. * symbol indicates statistical significance compared to
the M0 control cells. ***=p<0.001. NT= no treatment. N=3. M0 cells are unpolarized
cells. Cell states (M0, M1, M2) are indicated by light grey, dark grey, and black as indicated
by the key.
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Figure 19: Viability of J774A.1 cells treated with 30uM AhRa and then polarized for 24
hours. All treatments were performed 24 hours prior to staining with trypan blue and count-
ing on a hemocytometer. NT=not treated. N=3. Cell states (M0, M1, M2) are indicated by
light grey, dark grey, and black as indicated by the key.
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Figure 20: Raw264.7 cell viability on cells treated with cytokines for 24 hours via annexin
V and propidium iodide. Raw264.7 cells were treated with the appropriate cytokines or
endotoxin 24 hours prior to staining. Cells were gated using unstained cells and cells heat
shocked at 95oC for at least 30 minutes (NT dead). A) Shows percentage of live cells (cells
that did not stain) B) Percentage of early apoptotic cells C) Percentage of necrotic cells D)
Percentage of late apoptotic cells. NT=no treatment. N=3. Cell states (M0, M1, M2) are
indicated by light grey, dark grey, and black as indicated by the key.
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Figure 21: J774A.1 cell viability on cells treated with cytokines for 24 hours via annexin
V and propidium iodide. J774A.1 cells were treated with the appropriate cytokines or
endotoxin 24 hours prior to staining. Cells were gated using unstained cells and cells heat
shocked at 95oC for at least 30 minutes (NT dead). A) Shows percentage of live cells (cells
that did not stain) B) Percentage of early apoptotic cells C) Percentage of necrotic cells D)
Percentage of late apoptotic cells. NT=no treatment. * symbol indicates comparison to the
M0 control group. *= p <0.05, **= p <0.01. N=3. Cell states (M0, M1, M2) are indicated
by light grey, dark grey, and black as indicated by the key.
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Figure 22: Raw264.7 cell viability on cells treated with 30µM AhRa and cytokines for
24 hours via annexin V and propidium iodide. Raw264.7 cells were treated with 30µM
AhRa and the appropriate cytokines or endotoxin 24 hours prior to staining. Cells were
gated using unstained cells and cells heat shocked at 95oC for at least 30 minutes (NT
dead). A) Shows percentage of live cells (cells that did not stain) B) Percentage of early
apoptotic cells C) Percentage of necrotic cells D) Percentage of late apoptotic cells. *
symbol indicates comparison to the live M0 control group. ***= p<0.001. N=3. Cell
states (M0, M1, M2) are indicated by light grey, dark grey, and black as indicated by the
key.
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Figure 23: J774A.1 cells viability on cells treated with 30µM AhRa and cytokines for
24 hours via annexin V and propidium iodide. J774A.1 cells were treated with 30µM
AhRa and the appropriate cytokines or endotoxin 24 hours prior to staining. Cells were
gated using unstained cells and cells heat shocked at 95oC for at least 30 minutes (NT
dead). A) Shows percentage of live cells (cells that did not stain) B) Percentage of early
apoptotic cells C) Percentage of necrotic cells D) Percentage of late apoptotic cells. *
symbol indicates comparison to the live M0 control group. *= p <0.05, **= p <0.01 ***=
p <0.001. N=3. Cell states (M0, M1, M2) are indicated by light grey, dark grey, and black
as indicated by the key.
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Figure 24: Fold change comparison of Raw264.7 cells stained with annexin V and PI. Re-
sults from Figures 20 and 22 are compared against each other (N=3 for all experimetnts).
A) Live cell comparisons from both experiments. B) Early apoptotic cell comparisons from
both experiments. C) Necrotic cell comparisons from both experiments D) Late apoptotic
cell comparisons from both experiments. * symbol indicates comparison to the correspond-
ing live M0 control group. ***= p <0.001.
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Figure 25: Fold change comparison of J774A.1 cells stained with annexin V and PI. Results
from Figures 21 and 23 are compared against each other (N=3 for all experiments). A) Live
cell comparisons from both experiments. B) Early apoptotic cell comparisons from both
experiments. C) Necrotic cell comparisons from both experiments D) Late apoptotic cell
comparisons from both experiments. * symbol indicates comparison to the corresponding
live M0 control group. *= p <0.05, **= p <0.01 ,***= p <0.001.
56
Discussion
The goal of this study was to examine the effects of an AhR antagonist on the expression
of MHCI and MHCII molecules in Raw264.7 and J774A.1 murine macrophages. These
cell lines were chosen because they are often used as a model for comparison to primary
murine macrophages and therefore widely recognized for study of the innate immune sys-
tem. During the course of the study, cells treated with 30µM AhRa, LPS, and IFNγ showed
higher cell viability than cells treated with only LPS and IFNγ. This lead me to examine
cell death in both cells lines with annexin V and PI before and after the addition of the
AhRa. Because the AhR has been shown to influence apoptosis and the levels of MHC
expression [43, 45, 75], it was important to examine the endogenous in vitro effects of the
AhR on macrophages.
As shown in Figure 12, MHCII expression is significantly up-regulated in Raw264.7
cells exposed to IFNγ, LPS, or LPS & IFNγ. These data match the reported trends in
literature [8]. The J774A.1 cells did not express detectable levels of MHCII expression in
the M1 cells (Figure 8). Perhaps there is a defect that keeps this cell line from expressing
MHCII in significant quantities. Since MHCI expression was consistent in both cell lines, it
is unlikely that the defect has to do with signaling via NLRC5 (Figure 1). Because MHCII
expression was not increased after the addition of LPS or IFNγ, the most likely defects are
probably found in either the IFNγ or TLR4 pathways.
Perhaps the IFNγ receptor (IFNGR) subcomponents do not dimerize as they should.
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It is possible that IFNGR1 and IFNGR2 or Jak1 and Jak2 cannot bind together. This inabil-
ity to bind would not allow the IFNGR to bind STAT1 and upregulate IRF1 and NLRC5
(Figure 1). It is also possible that the IFNGR is functional, but there is a defect in the
NFκB signaling pathway. If NFκB signaling was defective, the MHC complex would fail
to be significantly upregulated (Figure 1). Additionally, there could be a defect in TRAF6
or TAK1 signaling which would cause decreased MHCII expression due to lack of MAPK
activity (Figure 2). Perhaps there is not one single defect in the J774A.1 cells and instead
there are several.
Although the AhR exists in both cell lines, Figures 9 and 10 show that the J774A.1
cell line expressed greater percentages of the AhR than the Raw264.7 cell line. At this
time, I have found nothing in published literature that directly measured AhR expression
in J774A.1 or Raw264.7 macrophages. However, Kimura et al. [33] found that LPS and
TLR ligands induced AhR expression in murine macrophages. My data confirm that AhR
expression is upregulated in Raw264.7 murine macrophages after activation with LPS (Fig-
ure 9). Curiously, the J774A.1 cells showed high amounts of AhR expression in M0 and
M1 cells and low amounts of AhR expression in M2 cells (Figure 10). Because this part
of the study was done as an N of 1, it should be repeated to confirm that this pattern holds.
It is possible that the higher expression of the AhR in J774A.1 cells could influence the
expression of MHCII.
Fold change analysis on Raw264.7 cells between the cytokines only experiment (Fig-
ure 7) and the cytokines plus 30µM AhRa experiment (Figure 12) showed little difference
in MHCI expression (Figure 14). The fold change analysis also showed no change in
MHCII expression for M2 cells, however there was a decrease for all M1 cells treated
with 30µM AhRa (Figure 14). Although these results were not statistically significant, if
this study were repeated with the cytokines alone groups and the antagonist treated groups
compared on the same day, these results should show a significant suppression of MHCII
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expression. Treating the cells with an exogenous AhR ligand, such as TCDD, would help
to better define the role the AhR plays in MHCII expression on murine macrophages.
The data from the Raw264.7 cells support my hypothesis that there would be a de-
crease in MHCII expression after cells were treated with 30µM AhRa. My findings demon-
strate that the AhR affects MHCII expression. MHCII expression is directly tied to the
IFNγ and TLR4 pathways (Figures 1 and 2), and current scientific knowledge shows that
NFκB is involved with all three of these pathways [20, 33, 39, 52]. Furthermore, Kimura
et al. [33] found that STAT1 interacts with NFκB in murine macrophages. It is likely that
changing the expression of NFκB has a direct effect on AhR expression. These changes
could also affect MHCII expression and these relationships should be more closely exam-
ined in order to better understand this mechanism.
Fold change analysis on J774A.1 cells showed MHCI expression was unchanged be-
tween the experimental groups, which further supports my hypothesis that MHCI expres-
sion would not change. This phenomenon is most likely because MHCI expression can be
upregulated by multiple pathways, including CIITA and NLRC5. Upregulation of MHCII
expression must go through CIITA so I postulate that the additional method of upregula-
tion masks the changes in MHCI expression that may have occurred [36, 65]. The MHCII
fold change expression analysis showed that MHCII expression was significantly increased
in cells treated with IL-10 and IFNγ after treatment with AhRa. However it should be
noted that J774A.1 cells expressed very low amounts of MHCII compared to the Raw264.7
cells. The J774A.1 cells expressed a higher amount of AhR during M1 cell activation and
it could be that this extra AhR is causing less MHCII to be called to the plasma membrane.
It appears the AhR plays a role in the MHCII mechanism. The AhR has been shown to
work with Stat1 and NFκB to regulate LPS-induced inflammation [33]. There could be
suppressed activation of the NFκB pathway, or a lack of Stat1 signaling that is causing the
low MHCII stimulation.
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Figure 26 shows the pathway schematics for TLR4, IFNγ, and the AhR. It is known
that NFκB, the AhR, and STAT1 bind together [33]. I propose NFκB, the AhR, and STAT1
aggregate and bind to the MHC regulatory complex to upregulate the expression of MHCII
(Figure 26A). If this complex failed to assemble, it impacts the expression of MHCII after
the addition of 30µM AhRa in Raw264.7 cells (Figures 14). The J774A.1 cells showed
a lack of MHCII expression even with the addition of LPS or IFNγ (Figure 15). The
J774A.1 cells could have a defect in STAT1, which would result in cells failing to upregu-
late expression of MHCII (Figure 26B). A lack of STAT1 would prevent this complex from
forming, causing the lower MHCII expression. The relationship between the AhR and
MHCII should continue to be examined in order to better understand this inner working.
Cell viability via trypan blue exclusion showed there was a significant decrease in
viability for Raw264.7 cells treated with LPS & IFNγ (Figure 18), but treatment of the cells
with 30µM AhRa showed an increased viability. Because the AhR has been implicated in
cell cycle regulation and the apoptotic pathway [43, 45], this observation led me to test the
viability of the cells with annexin V and PI for apoptosis and necrosis. This assay showed
that Raw264.7 cells exhibited no change in early apoptosis and necrosis after treatment with
30µM AhRa (Figure 24). This trend differed from J774A.1 cells, which showed increases
in necrosis (Figure 25).
While J774A.1 cells stained with trypan blue did not show decreases in viability, I
wanted to see if the cells were possibly undergoing some apoptotic or necrotic processes
that were not readily apparent. The annexin V/PI staining showed that the J774A.1 cells had
increased necrosis across all experimental groups which was exacerbated by the addition
of 30µM AhRa (Figure 25). The J774A.1 cells showed higher overall amounts of AhR
(Figure 10). It could be this higher AhR expression protects these J774A.1 cells from
death by necrosis and late apoptosis better than the Raw264.7 macrophages (Figures 25
and 24). However these experiments should be repeated due to the high margins of error
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on the annexin V fold comparisons.
There are some limitations of this study. First, the cytokines alone study and the
cytokines with AhRa study were run on separate days and so fold comparisons had to be
used in order to make comparisons between the data sets. In the future, more caution
should be taken when designing the experiment to incorporate both of these conditions in
the same time frame. This adjustment will make it easier to compare the data and will
give more accuracy to the results because the data will not need to be normalized. Another
limitation of this study was that it only examined the effect of the AhR in the absence of
exogenous ligands, and therefore must represent either stimulation-induced AhR activation
or AhR activation by unknown endogenous ligands. Stimulation with exogenous ligand
may change the expression levels of MHCI or MHCII. In order to compare these conditions,
it would be necessary to expose the macrophages to AhR ligand and measure the expression
of MHC before and after the addition of AhRa.
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Figure 26: Proposed connections between the TLR4, AhR, and IFNγ pathways. Pictured
are the pathway schematics for IFNγ, TLR4 and the AhR. The pathways all interact with
NFκB. A) The AhR, STAT1, and NFκB have been shown to bind together to upregulate
MHCII expression. Here they could bind to MHC regulatory complex to help upregulate
the expression of MHCII. B) J774A.1 cells could have deficiencies in STAT1 binding,
resulting in decreased expression of MHCII. The increased expression of AhR in J774A.1
cells could result in a change in MHCII expression as well.
62
Future Studies
This study analyzed Raw264.7 and J774A.1 macrophage cell lines for the expression of
MHCI and MHCII molecules. The next step would be to compare these results to those
of primary mouse macrophages or primary human macrophages. Comparing established
cells lines to primary macrophages would allow you to see if there are potential differences
in the aryl hydrocarbon receptors. If the results are similar, then you could move on to
a mouse model where the mice have either knocked down or knocked out AhRs. The
AhR seems to exert a variety of different and important functions. Understanding more
about this receptor’s influence on cellular processes will help us understand cellular defense
mechanisms.
While the Raw264.7 cell line appears to be well characterized, it was difficult to find
information about the characterization of the J774A.1 cell line. Since both of these cell
lines are frequently used for comparison to primary cells, it would be beneficial to have
more data about the characterization of J774A.1 cells. My work shows that J774A.1 cells
did not produce significant quantities of MHCII even when LPS and IFNγ were both added
to the medium, while Raw264.7 cells produced significant quantities of MHCII with this
treatment. Understanding what caused this difference to occur may give us a more complete
understanding of what causes the up regulation of MHCII expression when macrophages
become activated.
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The relationship between the IFNγ receptor and the AhR should be examined. My
works shows that cells treated with AhR inhibitor and IFNγ showed increased MHCII
expression in RAW264.7 and J774A.1 cells (Figures 7 and 8). Cells treated with AhRa,
LPS, and IFNγ also show increased MHCII expression in Raw264.7 and J774A.1 cells. It
is possible there is a relationship between the activation of the AhR, the TLR4 receptor
and the IFNγ receptor. This relationship should be explored in order to understand how
these three receptors interact. The NFκB pathway has been shown to cross talk between
the TLR4, AhR, and IFNγ receptor pathways [2, 7, 11, 28, 29, 57]. Since all of these
pathways are involved in MHCI and MHCII expression, the NFκB expression levels should
be examined to see if there is a correlation between NFκ levels and the AhR.
The AhR is known to play a role in the apoptosis pathway, so it would be beneficial to
explore this further [43]. My study of cell viability with trypan blue showed there was an
increase of cell viability when the AhR was blocked in Raw264.7 cells, while there was no
difference in viability in J774A.1 cells. The results of my annexin V/PI study showed that
there was an increase in necrotic cells in the J774A.1 cells after the addition of AhRa. This
increase should be examined to see if there is any link between higher AhR expression and
protection from necrotic cell death.
It would be worth re-examining the results of the annexin V/PI assay with apoptosis
antibody kits that look for caspases or apoptotic enzymes in order to better understand how
this process could be delayed in activated macrophages. Kimura et al. (2013) report that
the activation of caspase 3 accelerates cell death in AhR defective macrophages. Looking
for the presence or absence of this and other specific cell death markers while they are in




The goal of this study was to demonstrate the impact of the AhR on the expression of MHCI
and MHCII in two murine macrophage cell lines. MHCI and MHCII signaling are involved
in proper immune response and T cell maturation, and without these molecules the function
of the immune system would be impeded [36, 54]. AhR signaling appears to be important
in a number of pathways, and here I provide evidence to support that the AhR is important
in both MHC regulation and cell death. I have demonstrated that MHCI expression did not
change after the addition of AhRa in both cell lines. When Raw264.7 cells were treated
with 30µM AhRa, MHCII expression decreased, while MHCII expression increased in
the J774A.1 cells. I also discovered that the J774A.1 cell line does not upregulate the
expression of MHCII in response to LPS or IFNγ. Annexin V/PI analysis showed an
increase in necrosis and apoptosis for J774A.1 cells that was not detectable by trypan blue
exclusion assay. The Raw264.7 cells also showed an increase in late apoptosis. These
results support the assumption that the AhR interacts with cell death pathways [43, 45, 75],
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Kunkel, S. L., Hültner, L., and Röcken, M. (2000). Mast cells control neutrophil
recruitment during T cell-mediated delayed-type hypersensitivity reactions through
tumor necrosis factor and macrophage inflammatory protein 2. The Journal of Exper-
imental Medicine, 192(10):1441–1452.
[5] Bigley, N. J. (2014). Complexity of interferon- γ interactions with HSV-1. Frontiers
in Immunology, 5(2):1–10.
[6] Bosisio, D., Polentarutti, N., Sironi, M., Bernasconi, S., Miyake, K., Webb, G. R., Mar-
tin, M. U., Mantovani, A., and Muzio, M. (2002). Stimulation of toll-like receptor 4
66
expression in human mononuclear phagocytes by interferon- gamma : a molecular ba-
sis for priming and synergism with bacterial lipopolysaccharide. Blood, 99(9):3427–
3432.
[7] Carlson, D. B. and Perdew, G. H. (2002). A dynamic role for the Ah receptor in cell
signaling? Insights from a diverse group of Ah receptor interacting proteins. Journal
of Biochemical and Molecular Toxicology, 16(6):317–325.
[8] Casals, C., Barrachina, M., Serra, M., Celada, A., Casals, C., Barrachina, M., Serra,
M., Lloberas, J., and Celada, A. (2007). Lipopolysaccharide up-regulates MHC class
II expression on dendritic cells through an AP-1 enhancer without affecting the levels
of CIITA. The Journal of Immunology, 178(10):6307–6315.
[9] Choi, E. Y., Lee, H., Dingle, R. W., Kim, K. B., and Swanson, H. I. (2012). De-
velopment of novel CH223191-based antagonists of the aryl hydrocarbon receptor.
Molecular Pharmacology, 81(1):3–11.
[10] Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., and Gusovsky, F. (1999).
Toll like receptor 4 mediates lipopolysaccharide-induced signal transduction. The
Journal of Biological Chemistry, 274(16):10689–10693.
[11] Cui, J., Zhu, L., Xia, X., Wang, H. Y., Legras, X., Hong, J., Ji, J., Shen, P., Zheng, S.,
Chen, Z. J., and Wang, R. F. (2010). NLRC5 negatively regulates the NF-kappaB and
type I interferon signaling pathways. Cell, 141(3):483–496.
[12] Darzynkiewicz, Z., Huang, X., Okafuji, M., and King, M. A. (2004). Cytometric
Methods to Detect Apoptosis. Methods in Cell Biology, 75(2):307–341.
[13] Darzynkiewicz, Z., Juan, G., Li, X., Gorczyca, W., Murakami, T., and Traganos, F.
(1997). Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell
67
death (necrosis). Cytometry, 27(1):1–20.
[14] de Waal Malefyt, R., Figdor, C. G., Huijbens, R., Mohan-Peterson, S., Bennett, B.,
Culpepper, J., Dang, W., Zurawski, G., and de Vries, J. E. (1993). Effects of IL-13 on
phenotype, cytokine production, and cytotoxic function of human monocytes. Com-
parison with IL-4 and modulation by IFN-gamma or IL-10. Journal of Immunology,
151(11):6370–6381.
[15] Denison, M. S. and Nagy, S. R. (2003). Activation of the aryl hydrocarbon recep-
tor by structurally diverse exogenous and endogenous chemicals. Annual Review of
Pharmacology and Toxicology, 43(1):309–34.
[16] Denison, M. S., Soshilov, A. A., He, G., Degroot, D. E., and Zhao, B. (2011). Exactly
the same but different: Promiscuity and diversity in the molecular mechanisms of
action of the aryl hydrocarbon (dioxin) receptor. Toxicological Sciences, 124(1):1–22.
[17] Devaiah, B. N. and Singer, D. S. (2013). CIITA and its dual roles in MHC gene
transcription. Frontiers in Immunology, 4:1–6.
[18] Duque, G. A. and Descoteaux, A. (2014). Macrophage cytokines: involvement in
immunity and infectious diseases. Frontiers in Immunology, 5(10):1–12.
[19] Epelman, S., Lavine, K. J., and Randolph, G. J. (2014). Origin and Functions of
Tissue Macrophages. Immunity, 41(1):21–35.
[20] Fitzgerald, K. A. (2001). Mal (MyD88-adaptor-like) is required for Toll-like receptor-
4 signal transduction. Nature, 413(9):78–83.
[21] Gartner, L. P. and Hiatt, J. L. (2009). Color Textbook of Histology. Saunders Elsevier,
Philadelphia, third edition.
68
[22] Gobin, S. J. P., Peijnenburg, A., Keijsers, V., and Van Den Elsen, P. J. (1997). Site
alpha is crucial for two routes of IFNgamma-induced MHC class I transactivation: the
ISRE-mediated route and a novel pathway involving CIITA. Immunity, 6(5):601–611.
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Appendix A- Gating Strategy for Flow
Cytometry Experiments Stained for
AhR, MHCI, and MHCII
This appendix contains the gating strategy for the flow cytometry experiments correspond-
ing to Figures 7-10 and 12-13. Figures 27 and 28 correspond to Figure 7. Figures 29 and
30 correspond to Figure 8. Figure 31 corresponds to Figure 9. Figure 32 corresponds to
Figure 10. Figures 33 and 34 correspond to Figure 12. Figures 35 and 36 correspond to
Figure 13.
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Figure 27: Raw cell gating strategy measuring MHCI expression for M1 and M2 trans-
formed cells. Raw cells were treated with cytokines and endotoxin for 24 hours prior to
MHCI staining and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percentage of cells that are positive for MHCI expression
after subtracting the isotype control data. A) Untreated Raw cells B) Raw cells treated with
IL4 C) Raw cells treated with IL10 D) Raw cells treated with IL13 E) Raw cells treated
with LPS F) Raw cells treated with IFNγ G) Raw cells treated with LPS and IFNγ
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Figure 28: Raw cell gating strategy measuring MHCII expression for M1 and M2 trans-
formed cells. Raw cells were treated with cytokines and endotoxin for 24 hours prior to
MHCII staining and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percentage of cells that are positive for MHCII expression
after subtracting the isotype control data. A) Untreated Raw cells B) Raw cells treated with
IL4 C) Raw cells treated with IL10 D) Raw cells treatd with IL13 E) Raw cells treated with
LPS F) Raw cells treated with IFNγ G) Raw cells treated with LPS and IFNγ
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Figure 29: J77 cell gating strategy measuring MHCI expression for M1 and M2 trans-
formed cells. J77 cells were treated with cytokines and endotoxin for 24 hours prior to
MHCI staining and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percentage of cells that are positive for MHCI expression
after subtracting the isotype control data. A) Untreatd J77 cells B) J77 cells treated with
IL4 C) J77 cells treated with IL10 D) J77 cells treated with IL13 E) J77 cells treated with
LPS F) J77 cells treated with IFNγ G) J77 cells treated with LPS and IFNγ
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Figure 30: J77 cell gating strategy measuring MHCII expression for M1 and M2 trans-
formed cells. J77 cells were treated with cytokines and endotoxin for 24 hours prior to
MHCII staining and analysis by flow cytometry. The experimental cell data were sub-
tracted from isotype control data. The black bar shows the difference between the two
parameters and the percent positive is the percentage of cells that are positive for MHCII
expression after subtracting the isotype control data A) Untreated J77 cells B) J77 cells
treated with IL4 C) J77 cells treated with IL10 D) J77 cells treated with IL13 E) J77 cells
treated with LPS F) J77 cells treated with IFNγ G) J77 cells treated with LPS and IFNγ
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Figure 31: Raw cell gating strategy measuring AhR expression for M1 and M2 transformed
cells. Raw cells were treated with cytokines and endotoxin for 24 hours prior staining for
AhR expression and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percent of cells that are positive for AhR expression after
subtracting the isotype control data. A) Untreated Raw cells B) Raw cells treated with IL4
C) Raw cells treated with IL10 D) Raw cells treated with IL13 E) Raw cells treated with
LPS F) Raw cells treated with IFNγ G) Raw cell treated with LPS and IFNγ
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Figure 32: J77 cell gating strategy measuring AhR expression for M1 and M2 transformed
cells. J77 cells were treated with cytokines and endotoxin for 24 hours prior staining for
AhR expression and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percent of cells that are positive for AhR expression after
subtracting the isotype control data. A) Untreated J77 cells B) J77 cells treated with IL4
C) J77 cells treated with IL10 D) J77 cells treated with IL13 E) J77 cells treated with LPS
F) J77 cells treated with IFNγ G) J77 cell treated with LPS and IFNγ
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Figure 33: Raw cell gating strategy measuring MHCI expression on M1 and M2 trans-
formed cells treated with 30µM AhRa. Raw cells were treated with 30µM AhRa for 1
hour and then cytokines and endotoxin were added for 24 hours prior to staining for MHCI
expression and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percentage of cells that are positive for MHCI expression
after subtracting the isotype control data. A) Untreated Raw cells B) Raw cells treated
with 30µM AhRa C) Raw cell treated with vehicle control D) Raw cells treated with 30µM
AhRa and IL4 E) Raw cells treated with 30µM AhRa and IL10 F) Raw cells treated with
30µM AhRa and IL13 G) Raw cells treated with 30µM AhRa and LPS F) Raw cells treated
with 30µM AhRa and IFNγ H) Raw cell treated with 30µM AhRa, LPS, and IFNγ
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Figure 34: Raw cell gating strategy measuring MHCII expression on M1 and M2 trans-
formed cells treated with 30µM AhRa. Raw cells were treated with 30µM AhRa for 1 hour
and then cytokines and endotoxin were added for 24 hours prior to staining for MHCII
expression and analysis by flow cytometry. The experimental cell data were subtracted
from isotype control data. The black bar shows the difference between the two parameters
and the percent positive is the percentage of cells that are positive for MHCII expression
after subtracting the isotype control data. A) Untreated Raw cells B) Raw cells treated
with 30µM AhRa C) Raw cell treated with vehicle control D) Raw cells treated with 30µM
AhRa and IL4 E) Raw cells treated with 30µM AhRa and IL10 F) Raw cells treated with
30µM AhRa and IL13 G) Raw cells treated with 30µM AhRa and LPS F) Raw cells treated
with 30µM AhRa and IFNγ H) Raw cell treated with 30µM AhRa, LPS, and IFNγ
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Figure 35: J77 cell gating strategy measuring MHCI expression on M1 transformed cells
treated with 30µM AhRa. J77 cells were treated with 30µM AhRa for 1 hour and then cy-
tokines and endotoxin were added for 24 hours prior to staining for MHCI expression and
analysis by flow cytometry. The experimental cell data were subtracted from isotype con-
trol data. The black bar shows the difference between the two parameters and the percent
positive is the percentage of cells that are positive for MHCI expression after subtracting
the isotype control data. A) Untreated J77 cells B) J77 cells treated with 30µM AhRa C)
J77 cells vehicle control D) J77 cells treated with 30µM AhRa and IL4 E) J77 cells treated
with 30µM AhRa and IL10 F) J77 cells treated with 30µM AhRa and IL13 G) J77 cells
treated with 30µM AhRa and LPS H) J77 cells treated with 30µM AhRa and IFNγ I) J77
cell treated with 30µM AhRa, LPS, and IFNγ
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Figure 36: J77 cell gating strategy measuring MHCII expression on M1 and M2 trans-
formed cells treated with 30µM AhRa. J77 cells were treated with 30µM AhRa for 1 hour
and then cytokines and endotoxin were added for 24 hours prior to staining for MHCII ex-
pression and analysis by flow cytometry. The experimental cell data were subtracted from
isotype control data. The black bar shows the difference between the two parameters and
the percent positive is the percentage of cells that are positive for MHCII expression after
subtracting the isotype control data. A) Untreated J77 cells B) J77 cells treated with 30µM
AhRa C) J77 cells vehicle control D) J77 cells treated with 30µM AhRa and IL4 E) J77
cells treated with 30µM AhRa and IL10 F) J77 cells treated with 30µM AhRa and IL13
G) J77 cells treated with 30µM AhRa and LPS H) J77 cells treated with 30µM AhRa and
IFNγ I) J77 cell treated with 30µM AhRa, LPS, and IFNγ
87
88
Appendix B- Gating Strategy for
Annexin V/Propidium Iodide Assays
This appendix contains the gating strategy for the Annexin V/PI cell death analysis.
Figure 37 corresponds to Figure 20. Figure 38 corresponds to Figure 21. Figure 39 corre-
sponds to Figure 22. Figure 40 corresponds to Figure 23.
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Figure 37: Raw cells treated with cytokines for 24 hours and stained with Annexin V and
propidium iodide. The cells were gated based on the unstained Raw cells. A) Unstained
Raw cells used for gating. B) Untreated Raw cells C) Raw cells heat shocked at 95oC for
30 minutes D) Raw cells treated with IL4 E) Raw cells treated with IL10 F) Raw cells
treated with IL13 G) Raw cells treated with LPS H) Raw cells treated with IFNγ I) Raw
cells treated with LPS and IFNγ
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Figure 38: J77 cells treated with cytokines for 24 hours and stained with Annexin V and
propidium iodide. The cells were gated based on the unstained J77 cells. A) Unstained
J77 cells used for gating. B) Untreated J77 cells C) J77 cells heat shocked at 95oC for 30
minutes D) J77 cells treated with IL4 E) J77 cells treated with IL10 F) J77 cells treated
with IL13 G) J77 cells treated with LPS H) J77 cells treated with IFNγ I) J77 cells treated
with LPS and IFNγ
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Figure 39: Raw cells treated with 30µM AhRa and cytokines for 24 hours and stained with
Annexin V and propidium iodide. The cells were gated based on the unstained Raw cells.
A) Unstained Raw cells used for gating. B) Untreated Raw cells C) Raw cells heat shocked
at 95oC for 30 minutes D) Raw cells treated with 30µM AhRa E) Raw cell vehicle control
F)Raw cells treated with 30µM AhRa and IL4 G) Raw cells treated with 30µM AhRa and
IL10 H) Raw cells treated with 30µM AhRa and IL13 I) Raw cells treated with 30µM
AhRa and LPS J) Raw cells treated with 30µM AhRa and IFNγ I) Raw cells treated with
30µM AhRa, LPS, and IFNγ
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Figure 40: J77 cells treated with 30µM AhRa and cytokines for 24 hours and stained with
Annexin V and propidium iodide. The cells were gated based on the unstained J77 cells.
A) Unstained J77 cells used for gating. B) Untreated J77 cells C) J77 cells heat shocked at
95oC for 30 minutes D) J77 cells treated with 30µM AhRa E) J77 cell vehicle control F)
J77 cells treated with 30µM AhRa and IL4 G) J77 cells treated with 30µM AhRa and IL10
H) J77 cells treated with 30µM AhRa and IL13 I) J77 cells treated with 30µM AhRa and
LPS J) J77 cells treated with 30µM AhRa and IFNγ I) J77 cells treated with 30µM AhRa,
LPS, and IFNγ
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